Clinical trial
Bevacizumab and Combination Chemotherapy in Patients With Lymph Node Positive…
NCT00119262 · National Cancer Institute (NCI), NIH · Completed
Key facts
| NCT number | NCT00119262 |
|---|---|
| Title | Bevacizumab and Combination Chemotherapy in Patients With Lymph Node Positive Breast Cancer |
| Official title | Phase II Feasibility Trial Incorporating Bevacizumab Into Dose Dense Doxorubicin and Cyclophosphamide Followed by Paclitaxel in Patients With Lymph Node Positive Breast Cancer |
| Lead sponsor | National Cancer Institute (NCI), NIH |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Male Breast Cancer, Stage II Breast Cancer, Stage IIIA Breast Cancer, Stage IIIB Breast Cancer |
| Intervention type | Biological, Drug, Radiation |
| Interventions | doxorubicin hydrochloride, cyclophosphamide, bevacizumab, paclitaxel, filgrastim, pegfilgrastim, radiation therapy, tamoxifen citrate, aromatase inhibition therapy |
| Enrollment | 226 |
| Start date | Oct 1, 2005 |
| Primary completion | Aug 1, 2009 |
| Completion | Sep 1, 2009 |
| First posted | Jul 13, 2005 |
| Last update posted | May 15, 2014 |
| Countries | United States |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: